Ricardo Brugés

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian, Kohei Shitara, Markus Moehler et al. · The Lancet · 2021 · 2.9K citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

Kohei Shitara, Jaffer A. Ajani, Markus Moehler et al. · Nature · 2022 · 442 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial

Yelena Y. Janjigian, Jaffer A. Ajani, Markus Moehler et al. · Journal of Clinical Oncology · 2024 · 216 citations · Full text

Medicine, Oncology, Gastrointestinal Oncology +1

Role of RUNX2 transcription factor in epithelial mesenchymal transition in non-small cell lung cancer: Epigenetic control of the <i>RUNX2</i> P1 promoter

Angélica María Herreño, Andrea Carolina Ramírez, Viviana Paola Chaparro et al. · Tumor Biology · 2019 · 40 citations · Full text

Medicine, Genetics, Oncology +15

Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649

Markus Moehler, Hong Xiao, Steven I. Blum et al. · Journal of Clinical Oncology · 2023 · 36 citations · Full text

Medicine, Cancer Biology, Oncology +15